HIV fatigue & brain fog — real evidence on HAND and what helps.

There is a particular kind of tired that people living with HIV describe to each other and rarely describe to a doctor. You slept eight hours and woke up flattened. You read the same paragraph three times. You walked into the kitchen for something and stood there. You lost a name mid-sentence — not a stranger's name, a friend's. You are managing a chronic condition well, your labs look good, and something about your own mind feels slower and less reliable than it used to.

That experience has a research literature behind it, and the literature is more supportive of you than most clinic conversations are. Cognitive symptoms in HIV are common enough to have a formal name, formal diagnostic criteria, a thirty-year research history, and an active scientific argument about how best to define them. Fatigue is one of the most frequently reported symptoms in HIV care, including among people whose virus is fully suppressed.6 Neither of those things is in your head — and both are workable.

Start here: this is documented, not imagined

The single most useful thing to know is that clinicians studying HIV and the brain have been measuring what you are describing for decades, and they keep finding it. The largest and most cited American study of the question — the CNS HIV Antiretroviral Therapy Effects Research cohort, universally called CHARTER — enrolled 1,555 adults living with HIV at six United States university clinics and gave every one of them a comprehensive neuropsychological battery. Fifty-two percent showed neuropsychological impairment.2 That is not a small subgroup. That is most of a coin flip.

More recent work puts neurocognitive impairment in roughly 40% of people living with HIV, with the domains most often affected being processing speed, attention, working memory, and cognitive flexibility.4 Read that list again, because it is remarkably close to the plain-language version people actually use: everything takes longer, I lose my place, I can't hold two things in my head, switching tasks wrecks me. The research language and the kitchen-table language are describing the same thing.

Fatigue tracks alongside it. In the Multicenter AIDS Cohort Study, 25% of participants reported persistent fatigue and 26% reported being excessively sleepy — and the clinicians reviewing that data were blunt that fatigue is one of the most commonly reported symptoms among people living with HIV, including people with fully suppressed virus.6 Sleep disturbance is similarly widespread: a 2024 meta-analysis pooling 43 studies and 28,480 people living with HIV found a self-reported sleep disturbance prevalence of 52.29%, against a general-population estimate of about 30%.7

Why nobody told you

Several honest reasons, none of them your fault. A twenty-minute HIV visit tends to prioritize viral load, CD4 count, kidney function, and refills — the things with numbers attached. Cognitive symptoms have no lab value. They also sound, to an overworked clinician, like ordinary life: everyone is tired, everyone forgets things, everyone is on their phone too much. And there is a legitimate scientific dispute about how loosely the diagnostic criteria should be applied, which has made some clinicians cautious about naming it at all.4

The result is a gap where people fill in the worst explanation available. Many assume they are developing dementia. Many assume they are lazy, depressed in a way that is their own fault, or aging badly at forty-five. The actual answer is usually more mundane and far more actionable: several ordinary, treatable contributors stacked on top of each other, sometimes with a measurable HIV-related component underneath, and each layer worth addressing separately.

What HAND actually is — the Frascati categories

In 2007, a working group convened with support from the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke published updated research criteria for HIV-associated neurocognitive disorders in Neurology. Because the group met in Frascati, Italy, everyone calls them the Frascati criteria. That paper introduced the term asymptomatic neurocognitive impairment and set out an algorithm for sorting HIV-related cognitive findings into categories.1

There are three, and the difference between them is not how bad your test scores are alone — it is test scores plus whether daily life is affected.

Comorbidity changes the numbers dramatically

CHARTER did something important: it sorted participants by how much other medical and psychiatric complexity they carried. Impairment rates ran 40% in the group with minimal comorbidity, 59% with mild comorbidity, and 83% with severe comorbidity.2 The virus is one input among several, and the other inputs are often the ones you can change.

The study also found something that matters for long-term survivors specifically. Among participants with minimal comorbidity, a low CD4 nadir — the lowest your count ever went — was a strong predictor of impairment. People with suppressed virus and a nadir CD4 of at least 200 had the lowest impairment rate in the cohort, 30%, compared with 47% in otherwise comparable participants.2 If you were diagnosed late, or spent years before effective treatment existed, that history is legible in the data. It is not a moral fact about you; it is a reason to be taken seriously now.

That mechanism is worth holding onto, because it explains why suppression is necessary but not automatically sufficient. HIV works on the brain indirectly, through the supporting cells and the immune signaling around neurons, which is why federal neurologists describe cognitive difficulty persisting in some people even on well-controlled treatment — and note that some antiretrovirals do not cross the blood-brain barrier well.3

The live argument: is Frascati too loose?

You deserve to know that the field is currently rethinking these categories. A 2025 review in Brain Communications reports that the Frascati approach is increasingly challenged, that its high false-positive rate has been considered problematic and stigmatizing, and that an expert consensus has proposed replacing the framework with the term HIV-associated brain injury.4 The concern is straightforward: if a definition labels a third of a population as impaired without any functional consequence, the label may be doing more harm than the finding.

Practically, this means two things for you. First, a diagnosis of ANI is not a prophecy — it is a test result, and one that many researchers think is over-called. Second, the argument is about naming, not about existence. Nobody in that debate disputes that a meaningful share of people living with HIV have real cognitive symptoms that deserve real workup.

The diagnostic workup — what a good evaluation looks like

Start with your HIV clinician. This is not something you need a neurologist's blessing to raise, and going straight to a specialist often means a longer wait and a less complete picture, because your HIV clinician has your medication list, your nadir CD4, your comorbidities, and your labs already.

Step one: brief cognitive screening

The most widely used office screen is the Montreal Cognitive Assessment. The MoCA assesses short-term memory, visuospatial ability, executive function, attention, concentration and working memory, language, and orientation; it is validated for early detection of mild cognitive impairment, and its publisher reports sensitivity of 90% for mild cognitive impairment versus 18% for the Mini-Mental State Examination. HIV is among the conditions it lists, and it exists in paper, app, telephone, and videoconference forms, plus adapted versions for people with hearing or visual impairment or limited formal education.11

Be aware of an honest limitation. The 2025 Brain Communications review found that both the MMSE and the MoCA showed insufficient sensitivity for detecting neurocognitive impairment specifically in people living with HIV, and instead recommends a short structured screen asking directly about memory, executive function, and attention.4 An earlier HAND review reached a similar conclusion about brief screens generally — that they are neither sensitive nor specific enough for HAND.1 Translation: a normal MoCA does not mean nothing is wrong. If your symptoms are real and the screen comes back normal, that is a reason to keep going, not to stop.

Step two: full neuropsychological testing

A formal battery is the actual diagnostic standard, and it is a different animal from a ten-minute screen — typically two to four hours with a neuropsychologist, covering seven domains with instruments such as the Hopkins Verbal Learning Test–Revised for verbal learning and memory, digit span for working memory, Trail Making B and the Stroop and Wisconsin Card Sorting tests for executive function, the Rey–Osterrieth figure for visuospatial construction, Digit Symbol and the Symbol Digit Modalities Test for processing speed, and the Grooved Pegboard and finger tapping for motor function.4

Norms matter enormously here, and this is a place where inequity gets baked into results. Neuropsychometric performance is substantially influenced by social and economic factors, and appropriate local normative data is essential — testing that ignores education, language, and cultural context will misclassify people.1 If English is not your first language, or your schooling was interrupted, say so before testing begins and ask what norms will be used.

Step three: imaging, labs, and spinal fluid when indicated

Neuroimaging in this context is mostly about ruling other things out. Current recommendations include brain MRI to screen for other central nervous system pathology, and lumbar puncture to rule out cerebrospinal fluid viral escape — a situation where HIV is replicating in the central nervous system despite blood suppression. For people over 55, cerebrospinal fluid beta-amyloid and phosphorylated tau can help distinguish an Alzheimer's process.4 Federal materials add that magnetic resonance spectroscopy can show decreases in chemicals related to nerve cells and increases in chemicals related to inflammation, and that cerebrospinal fluid analysis can sample the virus affecting the brain directly.3

Nobody should be doing all of this at once. A reasonable sequence is: screen, treat the obvious reversible contributors, retest, and escalate to imaging or lumbar puncture only if symptoms persist or progress after the treatable layers are addressed.

Differential diagnosis — what else causes exactly these symptoms

This is the most important section in the article, because the most common cause of HIV-related brain fog is frequently not HIV. Formal HAND criteria themselves require that other causes of cognitive impairment be ruled out and that the confounding effects of substance use and psychiatric illness be considered.1 The differential is not a delay tactic; it is the diagnosis.

Here is what belongs on the list, roughly in order of how often it turns out to be the answer.

• Sleep-disordered breathing. Obstructive sleep apnea is strikingly common and strikingly under-recognized in HIV, and its symptoms are often attributed to HIV itself.6 Full detail in the next section.
• Insomnia and poor sleep quality. In one urban HIV cohort, 75% had poor sleep quality by the Pittsburgh Sleep Quality Index and 52% met insomnia criteria, against roughly 30% and 10% in the general population.8
• Depression. Pooled prevalence across 240 studies is 31%.14 Depression impairs concentration, memory, and processing speed directly.
• Anxiety. Pooled prevalence 29%, and anxiety is independently associated with sleep disturbance in HIV.147
• Thyroid dysfunction, B12 or folate deficiency, anemia, and — in men — low testosterone. All produce fatigue and cognitive slowing, all are blood tests, all are treatable. These are standard parts of any fatigue workup and cost very little to check.
• Medication effects. Federal treatment guidelines state that psychiatric disorders may be exacerbated by efavirenz, rilpivirine, and, infrequently, by integrase strand transfer inhibitors.10 Insomnia and sleep disturbance are the most prevalent neuropsychiatric symptoms reported with dolutegravir.20
• Vascular and metabolic comorbidity. Type 2 diabetes, hyperlipidemia, current smoking, and previous cardiovascular disease are each significantly associated with global neurocognitive impairment in people living with HIV.19
• Substance use. Real effects, discussed later without moralizing.
• Cerebrospinal fluid viral escape. Uncommon, but a specific and treatable situation worth excluding when symptoms are persistent and unexplained.4

Notice the shape of that list. The top entries are the most common and the most treatable, and the HIV-specific explanation sits near the bottom. That ordering is the single most useful thing to bring into an appointment, because it is the opposite of how most people — and some clinicians — instinctively approach it.

Sleep and fatigue — the most commonly missed cause

If you read only one section, read this one. The sleep data in HIV is genuinely startling, and it is where the biggest gap between what is happening and what is being diagnosed sits.

Obstructive sleep apnea is far more common than it is diagnosed

In a polysomnography subset of the Multicenter AIDS Cohort Study, 70% of participants living with HIV met criteria for obstructive sleep apnea — and only 12% of those with apnea were obese.6 That second number matters, because the mental image of sleep apnea most people and many clinicians carry is a heavy, snoring, middle-aged man. In HIV, that stereotype actively causes missed diagnoses.

The diagnostic gap is enormous. Across a veterans cohort, an urban clinic, and a CFAR clinic population, only about 4% of people living with HIV carried a diagnosis of obstructive sleep apnea — compared with 12.4% of people without HIV in the same veterans cohort. For context, roughly 10% of the United States population has clinically important obstructive sleep apnea, with estimates of about 13% in middle-aged men and 6% in middle-aged women.6 So the population with the highest measured burden has the lowest diagnosis rate.

The clinicians who assembled that evidence were direct about the mechanism of the miss: common obstructive sleep apnea symptoms such as fatigue and tiredness are often ascribed to HIV itself. In the MACS data, the strongest predictor of fatigue was witnessed apnea — someone else noticing you stop breathing. Their recommendation was equally direct: clinicians caring for people living with HIV should consider obstructive sleep apnea when evaluating fatigue, tiredness, or excessive sleepiness. Existing screening questionnaires are a reasonable starting point, home sleep testing is widely available, and CPAP remains the gold-standard treatment.6

Insomnia and sleep quality

Sleep problems in HIV are not only about breathing. In an urban HIV cohort, 75% of participants had poor sleep quality by the Pittsburgh Sleep Quality Index and 52% met criteria for insomnia — versus general-population figures of roughly 30% and 10%. Higher apnea risk in that cohort was associated with older age, male sex, body mass index of 30 or above, and metabolic comorbidities.8

The larger 2024 meta-analysis found the pooled self-reported sleep disturbance prevalence of 52.29% across 43 studies, with wide variation by instrument — 57.81% with the Pittsburgh Sleep Quality Index versus 28.46% with the Insomnia Severity Index. Adjusting for publication bias lowered the pooled estimate to 38.88%. Comorbid depression and anxiety, and time since HIV diagnosis, were significant moderators, and prevalence was highest in North American studies at 62.81%.7

Two takeaways from that spread. The honest range is roughly 39% to 52% depending on how you measure, which is still far above the general population. And depression and anxiety are woven through the sleep picture rather than separate from it — which is exactly why the next section exists.

Depression, anxiety, and the cognitive symptoms they cause

Depression does not just make you sad. It slows processing speed, fragments attention, degrades working memory, and impairs the retrieval of things you actually learned — a pattern so convincingly like a neurodegenerative process that clinicians historically called it pseudodementia. In HIV, that overlap is not a curiosity; it is a routine diagnostic problem, because a mild neurocognitive disorder and a moderate depression can look nearly identical from the outside.

The scale of the overlap is large. A meta-analysis of 240 studies found pooled prevalences among people living with HIV of 31% for depression, 29% for anxiety, 20% for suicidal ideation, 20% for post-traumatic stress disorder, 47% for stigma, and 44% for psychological distress.14 Those last two are worth pausing on. Stigma at 47% and psychological distress at 44% are not soft findings — they are the most prevalent items on the list, and they describe an environment, not a personal deficiency.

The two screens to ask for by name

The PHQ-9 is nine questions scoring each of the nine DSM criteria for depression from 0 to 3. Validated against structured mental health professional interviews in 580 people, a score of 10 or above had 88% sensitivity and 88% specificity for major depression; scores of 5, 10, 15, and 20 mark mild, moderate, moderately severe, and severe depression.12 It takes about two minutes.

The GAD-7 asks how often, over the past two weeks, you have been bothered by seven anxiety-related problems — feeling nervous or on edge, being unable to stop worrying, worrying too much about different things, trouble relaxing, restlessness, irritability, and feeling afraid something awful might happen. Total scores run 0 to 21, with 5, 10, and 15 marking mild, moderate, and severe anxiety.13

Both are short, free, standard, and already in most electronic health records. There is no good reason for a fatigue-and-fog conversation to happen without them.

When to treat depression as the cognitive problem

If your PHQ-9 is 10 or higher, treating depression is not a detour on the way to a cognitive workup — it is the first step of the cognitive workup. Two reasons. Practically, if depression is driving the symptoms, treating it resolves them, and you will have avoided months of testing. Diagnostically, neuropsychological testing performed during an untreated moderate depression will be difficult to interpret, and may generate a label that follows you around.

Federal neurologists list antidepressants among the treatments used for HIV-related neurological and cognitive difficulty, alongside anticonvulsants and — notably — the observation that psychostimulants may also improve depression and reduce fatigue.3 That last point is worth raising with a clinician if fatigue rather than mood is the dominant symptom.

One caution. If a clinician stops at "it's just depression" and never revisits the cognitive question after your mood improves, that is an incomplete workup. The correct sequence is treat, wait, reassess. Both things can be true at once, and often are.

Antiretrovirals and cognition — what to know before switching

This is a section where the internet is louder than the evidence, so it is worth being precise about what is established, what is plausible, and what has been tested and failed.

What the treatment guidelines say

Federal HIV treatment guidelines state plainly that psychiatric disorders may be exacerbated by efavirenz, rilpivirine, and, infrequently, by integrase strand transfer inhibitors. The same guidelines list neuropsychiatric events among the long-term adverse effects that warrant ongoing attention, and note that genetic factors predisposing some people to adverse effects include efavirenz neuropsychiatric toxicity — from a drug the guidelines describe as no longer commonly used in clinical practice.10

Efavirenz is the historical anchor of this conversation. Vivid dreams, dizziness, mood change, and difficulty concentrating were common enough that they shaped a generation's experience of treatment. If you have been on the same regimen for many years, it is worth asking what you are actually taking, because for some long-term survivors this is a fixable legacy problem rather than a permanent condition.

The integrase inhibitor question, honestly stated

A published review of neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors reports that these events are usually mild to moderate; that the most prevalent symptoms are insomnia and sleep disorders, with a spectrum including dizziness, anxiety, depression, headache, paraesthesia, musculoskeletal pain, poor concentration, and slow thinking; and that across recent cohort studies involving more than 6,400 people, discontinuation rates due to neuropsychiatric adverse events were around 3.5%, with a range of 1.4% to 7.2%. Those rates were higher than in randomized trials and higher than with elvitegravir or raltegravir, with older people, women, and people starting abacavir simultaneously appearing more vulnerable in some cohorts.20

Read that carefully in both directions. "Poor concentration and slow thinking" appearing on a list of recognized medication effects means your experience has a documented alternative explanation that is not brain damage. And a roughly 3.5% discontinuation rate means the large majority of people on these regimens do not have this problem — so this is a question to ask, not an assumption to act on.

What has been tried and has not worked

Two intuitive strategies have been tested and come up empty, which is worth knowing before you push for either.

• Higher central nervous system penetration. A randomized trial of 16 weeks of higher versus lower central-nervous-system-penetration-effectiveness regimens in 49 people found no difference in cognitive outcomes, and there is concern that higher penetration may itself be neurotoxic.4
• Treatment intensification. A randomized trial adding maraviroc, with or without dolutegravir, to existing therapy failed to improve cognition.4

What has shown signal is narrower and more specific: switching away from a medication that is causing you problems. The same review notes that switching to medications with a more favourable effect on cognition has been shown to improve both subjective and objective cognitive function.4 That is a targeted intervention for a suspected drug effect — not a general cognitive enhancement strategy.

Pacing and cognitive rehabilitation — what the trials show

Two different strategies get grouped together here. Pacing is about managing a limited daily energy budget. Cognitive rehabilitation is about training or compensating for specific cognitive functions. The evidence base for the second is better than most people expect; the evidence base for the first, in HIV specifically, is thinner than it should be.

Pacing, honestly labelled

Pacing came out of the myalgic encephalomyelitis and chronic fatigue syndrome community, largely developed by people living with those conditions rather than handed down from clinical trials. The core principle is to work within an energy envelope rather than repeatedly overshooting it and paying for days afterward. In practice that means learning your own limit, stopping before you hit it rather than after, breaking demanding work into shorter blocks with real rest between them, and scheduling cognitively expensive tasks at whatever time of day you are sharpest.

We should be clear about the evidence status: this is a strategy borrowed from an adjacent condition, and randomized trials of pacing specifically in people living with HIV are not something we located. It is offered here as a practical approach with a plausible rationale and low risk, not as a proven treatment. Many people find it the single most useful change they make. That is worth saying without dressing it up as trial data.

Computerized cognitive training — the strongest rehabilitation evidence

Here the data is genuinely reasonable. A 2022 meta-analysis in JAMA Network Open pooled 12 randomized controlled trials with 596 participants living with HIV — 320 assigned to computerized cognitive training and 276 to control conditions. Standardized mean differences favored training across six domains: speed of information processing 0.65, attention and working memory 0.62, memory 0.59, abstraction and executive function 0.58, motor skills 0.50, and daily function 0.44. Verbal and language function and sensory-perceptual function did not reach significance. The authors graded the evidence as moderate quality for six domains, while noting real limitations: only 12 trials, allocation concealment reported in half, and about two-thirds unblinded.5

Effect sizes of 0.5 to 0.65 are moderate — not transformative, but comparable to plenty of interventions that get prescribed enthusiastically. The daily-function result at 0.44 matters most, because it suggests the gains are not confined to getting better at the training tasks themselves.

Broader reviews are more cautious. The 2025 Brain Communications neurorehabilitation review, surveying cognitive and computerized training trials in HIV alongside pharmacological approaches, concluded that truly compelling evidence for specific approaches is still lacking.4 Both statements can be true: the meta-analytic signal is real, and the overall field is early.

Medication for cognition and fatigue

One agent stands out in the review literature. A randomized trial of modafinil enrolled 103 people living with HIV and fatigue — 59 assigned to modafinil, 44 to placebo, over four weeks — and found improvement in processing speed on digit symbol testing, in non-dominant-hand Grooved Pegboard performance, and in subjective cognition on the Cognitive Failures Questionnaire. The reviewers described modafinil as one of the more promising agents while stating that the evidence remains low.4 Federal materials likewise note that psychostimulants may improve depression and reduce fatigue, alongside antidepressants, anticonvulsants, cholinesterase inhibitors, and physical therapy or rehabilitation.3

This is a legitimate thing to ask about, particularly if fatigue rather than mood or memory is the dominant symptom. It is also a controlled substance in most places, so expect a real conversation rather than a same-day prescription.

Comorbid drivers — the cardiovascular and metabolic layer

This section contains the most actionable news in the article, because these contributors are measurable, modifiable, and routinely treated in primary care.

A systematic review and meta-analysis in the Journal of the International Neuropsychological Society examined vascular risk factors and cognition in the combination antiretroviral therapy era. The systematic review covered 44 studies with 14,376 people living with HIV and 6,043 HIV-negative controls; the meta-analysis pooled 11 studies with 2,139 people living with HIV. Vascular risk factors were associated with roughly double the odds of global neurocognitive impairment — odds ratio 2.059 — and the association held after adjusting for clinical HIV variables. Looking at individual factors, type 2 diabetes, hyperlipidemia, current smoking, and previous cardiovascular disease were each significantly associated with global neurocognitive impairment. The domains most affected were attention and processing speed, executive functioning, and fine motor skills.19

Those affected domains are the same ones HIV itself hits hardest.4 Which means when someone living with HIV, diabetes, and high cholesterol has slowed processing speed, attributing all of it to the virus is a guess — and a guess that skips past the treatable part.

Silent strokes and small vessel disease

Brain injury does not have to announce itself. A cross-sectional study of 85 people living with HIV aged 50 or older in New York City — mean age 60, 78% non-Hispanic Black, most with well-controlled HIV — used brain MRI and magnetic resonance angiography to assess seven markers of cerebrovascular disease: silent brain infarcts, dilated perivascular spaces, microhemorrhages, white matter hyperintensity volume, two measures of white matter integrity, and intracranial large artery stenosis. Silent brain infarcts, intracranial large artery stenosis, and poor white matter integrity were each associated with worse performance in at least one cognitive domain, and the sum of those three markers was associated with lower working memory, poorer list learning, and lower global cognition. The authors framed all three as potentially modifiable exposures.18

"Silent" means these strokes cause no stroke symptoms at the time. They accumulate quietly and show up as cognitive change years later. That is the strongest argument in this article for treating blood pressure, lipids, blood sugar, and smoking as brain-health interventions rather than heart-health interventions you will get around to eventually.

Statins, hepatitis C, and what we could not verify

Two things belong here that we could not source to our standard, and we would rather say so than fill the gap. We did not locate primary evidence in this research session on statins improving cognition in people living with HIV, and we are not going to imply a benefit that we have not verified — though the meta-analytic finding that hyperlipidemia is associated with impairment is itself a reason to treat lipids.19 Similarly, we did not verify HIV/hepatitis C coinfection cognitive data directly in this session. If you are living with both, raise cognitive symptoms with whoever manages your hepatitis C care, since curative treatment exists and is worth pursuing on its own merits.

Substance use and cognition — real effects, no moralizing

The Frascati criteria require considering the confounding effect of substance use before diagnosing HAND.1 That is a clinical requirement, not a judgment, and it is worth engaging with honestly rather than defensively — because the effects are real and, importantly, they are not permanent verdicts.

Methamphetamine: the clearest signal

A study of 200 participants across four groups — living with HIV and methamphetamine dependent, methamphetamine dependent without HIV, living with HIV without methamphetamine dependence, and neither — gave everyone a comprehensive, demographically corrected neuropsychological battery. Global impairment rates were 58% in the group with both, 40% with methamphetamine dependence alone, 38% with HIV alone, and 18% with neither. The pattern was a significant monotonic trend, and the authors concluded that HIV and methamphetamine dependence are each associated with neuropsychological deficits and that in combination the effects appear additive.15

Note what that data does not say. It does not say people who use methamphetamine caused their own cognitive problems, and it does not say 58% is a ceiling you are stuck at. Cognitive function after stimulant use often improves with sustained reduction or abstinence. What the data supports is a practical point: if methamphetamine is part of your life and cognition is a concern, disclosing that to your clinician changes the workup and the plan for the better.

Alcohol and cannabis

Chronic heavy alcohol use damages cognition through several well-established routes, including thiamine deficiency and direct neurotoxicity, and it interacts badly with sleep architecture — alcohol shortens the time to fall asleep and degrades the quality of what follows. It also worsens sleep-disordered breathing. If you drink daily and wake up unrefreshed, that is a mechanism, not a mystery.

Cannabis is more complicated and deserves its own treatment, which we give it on our companion page. Frequent heavy use has documented effects on learning, memory, and attention that overlap directly with what a HAND workup is trying to measure — which makes it a variable to declare rather than conceal.

The harm reduction frame

Nothing above is an argument for shame, and shame is a poor clinical tool anyway. The useful frame is information: tell your clinician what you actually use, how often, and by what route, so that cognitive findings can be interpreted correctly and so that reduction — if you want it — can be supported rather than lectured about. Ryan White–funded programs cover support services alongside medical care precisely because these things are not separable.21 A provider who responds to honest disclosure with stigma is giving you information too: that you may need a different provider.

Accommodations — your rights at work and at school

Cognitive fatigue is one of the most under-accommodated experiences in HIV, largely because people do not know that the legal framework already covers it. It does.

The Equal Employment Opportunity Commission's guidance on HIV in the workplace states that if your job performance could be affected by HIV, the side effects of HIV medication, or another medical condition that has developed because of HIV, you may be entitled to a reasonable accommodation. It defines a reasonable accommodation as a change in the way things are done that you need because of a disability, and lists examples that map directly onto cognitive fatigue: altered break and work schedules, including frequent breaks to rest and modified schedules to accommodate medical appointments; changes in supervisory methods, such as written instructions from a supervisor who usually does not provide them; ergonomic office furniture; unpaid time off for treatment or recuperation; permission to work from home; and reassignment to a vacant position. The guidance is explicit that these are only examples and that you are free to request any change you need because of your condition.16

"Written instructions from a supervisor who usually does not provide them" is the accommodation almost nobody asks for and many people need. If verbal instructions evaporate before you reach your desk, that is a documented, named, legitimate accommodation request — not a confession of incompetence.

How to ask, and when

The process is simpler than people fear. Tell a supervisor, HR manager, or other appropriate person that you need a change to the way things are normally done because of a medical condition — you may ask at any time. Your employer may ask you to put the request in writing and describe how your condition affects your work, and may ask for a letter from your doctor documenting the condition and the need. Your doctor may also be asked whether particular accommodations would meet your needs.16

Timing matters more than most people realize. Because an employer does not have to excuse poor job performance, even when it was caused by a medical condition or medication side effects, the EEOC's own guidance says it may be better to ask for an accommodation before problems occur or get worse.16 Ask early, in writing, while your reviews are still good. What an employer does not have to do is remove the essential functions of your job, let you do less work for the same pay, or accept lower-quality work.16

Documentation strategies

Whether the underlying finding is HAND, medication effects, treated sleep apnea with residual symptoms, or depression, the accommodation request is about function, not diagnosis. Useful documentation describes what you cannot reliably do and what change would fix it: sustained attention limited to roughly 45 minutes, requiring short scheduled breaks; difficulty retaining multi-step verbal instructions, requiring written follow-up; reduced tolerance for open-plan noise, requiring a quiet workspace or noise-cancelling equipment; slowed processing speed, requiring extended deadlines on complex written work. Ask your clinician to write in those terms. A neuropsychological report, if you have one, is strong supporting evidence.

For students, the parallel framework in United States public schools and federally funded institutions is a Section 504 plan, which functions similarly to a workplace accommodation and can include extended test time, reduced-distraction testing environments, note-taking support, and attendance flexibility for medical appointments. Start with your school's 504 coordinator or your college's disability services office. We were not able to verify current federal Section 504 guidance documents in this research session, so treat the specific accommodation examples above as commonly requested rather than as a citation of federal rule text.

What actually helps — ranked by evidence

Here is the honest hierarchy, strongest evidence first.

1. Treat the sleep problem

Given that 70% of a polysomnography subset had obstructive sleep apnea while only around 4% of people living with HIV carry the diagnosis,6 and that roughly 39% to 52% report sleep disturbance depending on measurement,7 this is the highest-yield action available. It has the largest gap between prevalence and diagnosis, an established gold-standard treatment in CPAP, and accessible home testing.6

2. Treat depression and anxiety

Depression at 31% and anxiety at 29% pooled prevalence,14 two-minute validated screens with 88% sensitivity and specificity at a PHQ-9 cutoff of 10,12 and effective treatments that federal materials list among approaches used for HIV-related cognitive difficulty.3 Also: anxiety and depression are significant moderators of sleep disturbance prevalence,7 so treating them helps twice.

3. Exercise — with real caveats

The Exercise for Healthy Aging Study enrolled sedentary adults aged 50 to 75 — 32 people living with HIV and 37 controls — in 24 weeks of supervised endurance and resistance training three times weekly, randomizing at week 12 to continue at moderate intensity or advance to high intensity. Participants living with HIV started with poorer physical function, and both groups improved on every functional measure. Participants living with HIV showed greater percentage improvement in VO2 max over the first 12 weeks, and high-intensity training produced significantly greater strength gains for them — bench press up 6%, leg press up 10%. The authors concluded that adherence to at least the recommended 150 minutes per week of moderate-intensity or 75 minutes per week of high-intensity endurance exercise, plus regular resistance exercise, should be encouraged for all older people living with HIV.9

The caveat is specific and important: that trial measured physical function, not cognition. On exercise for cognition in HIV specifically, the 2025 review states that no conclusive data are available.4 So exercise has good evidence for function, fitness, and strength, plausible benefit for the vascular risk factors that are independently linked to cognitive impairment,19 and no proven direct cognitive effect in this population. If fatigue is your main symptom, start smaller than a protocol and build — pacing and exercise are not opposites, but overshooting your envelope is a real risk.

4. Computerized cognitive training

Moderate-quality evidence across 12 randomized trials and 596 participants, with standardized mean differences of 0.44 to 0.65 across six cognitive domains plus daily function.5 Low risk, low cost, real but modest benefit. Worth doing; not worth expecting miracles from.

5. Address the vascular and metabolic layer

Roughly double the odds of global neurocognitive impairment with vascular risk factors, with diabetes, hyperlipidemia, smoking, and prior cardiovascular disease each individually significant.19 Silent brain infarcts and poor white matter integrity are described as potentially modifiable exposures.18 This is ordinary chronic disease management doing double duty.

6. Review the regimen

Targeted, not general. Switching away from a medication with an unfavourable cognitive profile has been shown to improve subjective and objective cognitive function; increasing central nervous system penetration and intensifying therapy have both failed in randomized trials.4

What we could not verify — said plainly

The Mediterranean and MIND dietary patterns and mindfulness-based interventions are frequently recommended for cognitive symptoms, and we did not verify primary evidence for either in people living with HIV during this research session. We are naming them so you know they exist and so you know we did not confirm them, rather than dressing up a plausible recommendation as an evidence-based one. Both are low-risk. Neither should displace a sleep study.

Florida — where to get evaluated and who pays

Florida carries one of the largest HIV burdens in the country, with 4,606 new HIV diagnoses identified in the state in 2022 according to the Florida Department of Health.22 A large share of that population is aging with long-standing HIV, which is exactly the group for whom cognitive symptoms, vascular comorbidity, and sleep disorders converge.

The practical Florida problem is not usually eligibility — it is logistics. Neuropsychological testing is concentrated at academic medical centers and larger hospital systems, mostly in the Tampa Bay, Orlando, Jacksonville, Gainesville, and South Florida corridors. If you live in a rural county or the Panhandle, the nearest full battery may be a two-hour drive, and it is a half-day appointment you cannot easily do twice.

The transportation and case management angle

This is where Florida's patient care programs matter more than most people realize. The Florida Department of Health's HIV/AIDS section describes patient care programs for people living with HIV that may include health care, dental care, transportation, case management, housing, medication, and other services.22 Transportation and case management are the two that unlock a distant neuropsychology appointment. Ask your case manager specifically about medical transportation to a testing appointment — people routinely assume it only covers routine HIV visits.

Nationally, the Ryan White HIV/AIDS Program provides medical care, medications, and support services to help people stay in care, with Part B funding states and territories and providing medications through the AIDS Drug Assistance Program, Part A funding the cities and counties most affected, Part C funding outpatient ambulatory health services and support through local community-based groups, and Part D covering medical care and support for low-income women, infants, children, and youth. More than half of all people diagnosed with HIV in the United States — over 600,000 people — receive services through the program each year.21

One honest note on coverage. Whether a specific ADAP or Ryan White program in Florida pays for neuropsychological testing depends on local program rules and your insurance status, and we did not verify a Florida-specific coverage determination for cognitive assessment in this research session. Ask your case manager directly, get the answer in writing, and ask what the appeal path is if the first answer is no. If you are uninsured or underinsured, a Ryan White Part C clinic is generally the right place to start, since core medical services and support services are the program's purpose.21

Florida also runs free HIV care consultation lines for clinicians, including a general clinical questions line at 800-933-3413.22 If your provider is unsure how to work up cognitive symptoms in HIV, that number exists for exactly that kind of question — and pointing them to it is a reasonable thing to do.

Start here — the first three appointments

You do not need to do all of this. You need to start, in a sensible order, with the highest-yield things first.

Before your next visit

• Keep a two-week log. Sleep and wake times, how rested you feel, energy by time of day, and the specific cognitive failures — words lost, tasks abandoned, things reread. Specifics are far more useful to a clinician than "I'm tired all the time."
• Ask someone who sleeps near you whether you snore, gasp, or stop breathing. Witnessed apnea was the strongest predictor of fatigue in the MACS data.6
• Write down your regimen and when it last changed, plus any other medications and supplements. Timing relative to symptom onset is the key evidence for a drug effect.20
• Find out your lowest recorded CD4 count. Nadir CD4 was a strong predictor of impairment among CHARTER participants with minimal comorbidity.2

At the visit — the four asks

1. Screen sleep and mood first. PHQ-9, GAD-7, and an obstructive sleep apnea screen with a home sleep test if warranted.12136
2. Get the basic labs. Thyroid, B12 and folate, complete blood count, kidney and liver function, and testosterone if relevant.
3. Ask for a cognitive screen and get the symptoms documented. A MoCA is a reasonable start, with the caveat that brief screens can miss HIV-related impairment — so ask for the chart note either way.114
4. Ask whether your regimen could be contributing, and whether a switch is worth trialling if insomnia or concentration is the leading symptom.1020

Things you can start today, without permission

• Pace. Find your envelope, work inside it, stop before the wall rather than after it. Schedule the hardest thinking for your best hour.
• Externalize memory. Written lists, phone alarms, one calendar, notes taken during appointments. Compensation is a legitimate strategy, not a defeat.
• Move, in a dose you can sustain. The exercise evidence in HIV is strong for physical function and fitness, and the recommendation is 150 minutes weekly of moderate activity or 75 of vigorous, plus resistance work — built up gradually.9
• Request accommodations in writing, early. Before performance problems appear, per the EEOC's own advice.16
• Tell the truth about substances. It changes the workup for the better, and it is required to interpret cognitive findings correctly.1